Advanced Solid Tumor Clinical Trials & Research at Providence Medical Group

Providence Medical Group is currently enrolling patients for the following advanced solid tumor clinical trials:


Study of Magrolimab in Participants with Solid Tumors

Treatment: Mabrolimab + Docetaxel
PI: Ian Anderson, MD
Coordinator: Charity Behrend // charity.behrend@providence.org // (707) 521-3830 ext. 1181
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04827576
Sponsor: Gilead Sciences, Inc.


An Observational Study of the Human Adaptive Immune Response (SHAIR) to Cancer in Adults with Advanced Solid Malignancies

Treatment: N/A
PI: Sara Keck, MD
Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707) 521-3833 ext. 1313
Resources and Links: None
Sponsor: Atreca


A Phase II, Multicenter, Open-label study to evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02)

Treatment: Trastuzumab deruxtecan (T-DXd)
PI: Ian Anderson, MD
Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04482309
Sponsor: AstraZeneca


APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Treatment: Bozitinib (APL-101)
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03175224
Sponsor: Apollomics Inc.


A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors

Treatment: ABBV-927 with ABBV-368, budigalimab (ABBV-181), and/or chemotherapy
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03893955
Sponsor: AbbVie Inc.


SEERPRO: A Prospective Blood Sample Collection Study To Evaluate a Panel of Protein-based-Biomarkers

Treatment: Ibrutinib, Everolimus, Docetaxel, Paclitaxel, Cetuximab, Pembrolizumab
PI: Manasa Vulchi, MD
Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182


A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Treatment: ladiratuzumab vedotin
PI: Ian Anderson, MD
Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803 ext. 1103
Resources and Links: clinicaltrials.gov NCT No: NCT04032704


A Study of Repotrectinib(TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)

Treatment: Oral Repotrectinib
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: clinicaltrials.gov NCT No: NCT03093116


An Observational Study of the Human Adaptive Immune Response (SHAIR) to Cancer in Adults with Advanced Solid Malignancies (Atreca ATRC-000109SHAIR)

PI: Sara Keck, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org // (707) 521-3833 ext. 1313


Study of Magrolimab in Participants with Solid Tumors (GCT1046-04)

Treatment: Mabrolimab + Docetaxel
PI: Ian Anderson, MD
Coordinator: Charity Behrend // charity.behrend@providence.org // (707) 521-3830 ext. 1181
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04827576?term=Gilead+GS-US-548-5918&draw=2&rank=1
Sponsor: Gilead Sciences, Inc.

Our Providers

Our Locations